Drug Information

Drug (ID: DG01308) and It's Reported Resistant Information

• Name: Teicoplanin
• Synonyms: Targocid; Antibiotic 8327A; Teichomycin; MDL 507; Tecoplanina; Tecoplanine; Tecoplaninum; Teicoplanina; Teicoplanine; Teicoplaninum; Teico-planin; 61036-62-2; Teicoplanine [French]; Teicoplaninum [Latin]; Teicoplanina [Spanish]; Tecoplanine [INN-French]; Tecoplaninum [INN-Latin]; Tecoplanina [INN-Spanish]; Teicoplanine [INN-French]; Teicoplaninum [INN-Latin]; Teicoplanina [INN-Spanish]; UNII-4U3D3YY81M; Teicoplanin [USAN:INN:BAN]; 4U3D3YY81M; GTPL10924; BDBM512667; NSC 759183; 8327A
• Indication:
  In total 1 Indication(s)
  Bacterial infection [ICD-11: 1A00-1C4Z]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Bacterial meningitis [ICD-11: 1D02]; [1]
• Target: Bacterial Cell membrane (Bact CM); NOUNIPROTAC; [1]
• Formula: C88H97Cl2N9O33
• IsoSMILES: CCCCCCCCCC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)[C@H]([C@H]6C(=O)N[C@@H](C7=C(C(=CC(=C7)O)OC8[C@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C9=C(C=CC(=C9)[C@H](C(=O)N6)NC(=O)[C@@H]4NC(=O)[C@@H]1C2=CC(=CC(=C2)OC2=C(C=CC(=C2)[C@H](C(=O)N[C@H](CC2=CC(=C(O3)C=C2)Cl)C(=O)N1)N)O)O)O)C(=O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)NC(=O)C)Cl)CO)O)O
• InChI: 1S/C88H97Cl2N9O33/c1-3-4-5-6-7-8-9-10-60(108)94-68-74(113)71(110)58(32-101)129-87(68)132-78-55-26-40-27-56(78)126-52-18-14-38(24-47(52)90)77(131-86-67(92-34(2)103)73(112)70(109)57(31-100)128-86)69-84(121)98-66(85(122)123)45-29-42(105)30-54(127-88-76(115)75(114)72(111)59(33-102)130-88)61(45)44-23-37(13-15-49(44)106)63(81(118)99-69)96-83(120)65(40)97-82(119)64-39-21-41(104)28-43(22-39)124-53-25-36(12-16-50(53)107)62(91)80(117)93-48(79(116)95-64)20-35-11-17-51(125-55)46(89)19-35/h11-19,21-30,48,57-59,62-77,86-88,100-102,104-107,109-115H,3-10,20,31-33,91H2,1-2H3,(H,92,103)(H,93,117)(H,94,108)(H,95,116)(H,96,120)(H,97,119)(H,98,121)(H,99,118)(H,122,123)/t48-,57-,58-,59-,62-,63-,64+,65-,66+,67-,68-,69+,70-,71-,72-,73-,74-,75+,76+,77-,86+,87+,88 /m1/s1
• InChIKey: BJNLLBUOHPVGFT-CAYRISATSA-N
• PubChem CID: 133065662
• TTD Drug ID: D0K6MW

Type(s) of Resistant Mechanism of This Drug

  DISM: Drug Inactivation by Structure Modification

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-01: Infectious/parasitic diseases

Bacterial meningitis [ICD-11: 1D02]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Drug Inactivation by Structure Modification (DISM)

Key Molecule: D-alanine ligase (vanD5) [1]

• Molecule Alteration: Expression; Up-regulation
• Resistant Disease: Enterococcus faecium meningitis [ICD-11: 1D01.2]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Enterococcus faecium isolates; 1352
• Experiment for Molecule Alteration: Whole-genome sequencing assay
• Experiment for Drug Resistance: Broth dilution assay
• Mechanism Description: Glycopeptide (vancomycin and teicoplanin) resistance is attributed to the acquisition of vancomycin resistance (van) genes. Nine van genes that encode a D-Ala:D-Lac or D-Ala:D-Ser ligase (vanA, vanB, vanC, vanD, vanE, vanG, vanL, vanM and vanN) have been identified in Enterococcus spp. d-Alanyl:d-lactate (d-Ala:d-Lac) and d-alanyl:d-serine ligases are key enzymes in vancomycin resistance of Gram-positive cocci. They catalyze a critical step in the synthesis of modified peptidoglycan precursors that are low binding affinity targets for vancomycin.

References

• Ref 1: Emergence of vancomycin- and teicoplanin-resistant Enterococcus faecium via vanD5-harbouring large genomic island .J Antimicrob Chemother. 2020 Sep 1;75(9):2411-2415. doi: 10.1093/jac/dkaa220. 10.1093/jac/dkaa220